Ebola III – 2015 The year of the Plague?

This part III of the final installment of the Ebola journey. 2015 is looking to a very high contender for many events to converge. This last section is a post 6-month synopsis

from November 2014 to March 2015 and how circumstances have developed and the many conflicting reports to the control and spread of the BSL-4 pathogen

The following graphs seems to

elucidate one trend….

The lines seems to be on the upward

trend towards the end of 2014….

It would be prudent to assume this

trend will continue into the first 3

months of 2015, up to March….

The one factor that should be considered is

when spring approaches, and the weather

warms up, the cases will begin to rise….

“Published studies have included expression of Ebola virus protein subunits in live vaccinia virus vectors, selected DNA plasmids, Ebola virus-like particles, replication-competent vesicular stomatitis virus, Venezuela equine encephalitis virus replicons, recombinant parainfluenza virus type 3,

replication-defective recombinant adenovirus (rAd), and DNA combined with rAd prime-boost strategies (5, 12, 14, 19, 22, 24, 26, 31). Whilemany of these approaches have been evaluated in a nonhuman primate model (10), only DNA/rAd-, rAd-, or vesicular stomatitis virus-based vaccines

have shown efficacy in primates.”

Ok. People love their dogs. That’s a well established fact. However, dogs and cats are historically pathogen-carriers and should ‘UK’ have some kind of controlled outbreak, it will be seen whether this promise is acted out when reality bites at some future time. It is known through scientific papers that H3N2 has been fully transmitted to cats and Dogs.

The System will still notify the reader that Ebola is NOT airborne, but we know that some scientists have privately voiced concerns that this is a possibility if it not already.

It will be no surprise when nurses infected will be transported back to the ‘UK’ and put more people at risk due to the inefficient handling of what is

a BSL 4 pathogen with a 50% CFR as an average.

Mali is not out the picture just yet. The new VSV EBOV Z is being tested in the Malian population. Measles may also express at some future point.

It was positive to see one case where the

patient was relocated to the correct BSL-4

facility as was the situation in Italy.

It’s nice to see the BBC catching up

after months of ill-reporting. This

‘fact’ was divulged to you, the viewer,

way back in April 2014

This 90-day period of post-infection in

sperm was cited months ago while the

news and media attempted to spread

fear instead of real, genuine, helpful

information and data to inform the

public. The upwards trend of cases and

deaths still continue to rise (above

graph)

..Oddly , the news media inform the public 6,800 deaths, and yet 6 days before (December 10th chart

above) it was 500 less. Where these extra 500 cases emerged (or disappeared to) is not explained.

Are the death toll figures being exaggerated? PHE, December 5th

stated 6,070 deaths (previous slide). GAR reports 6,373 deaths and…

March 20th to April 4th 2015 are important occult dates to watch.

Coincidental or strange events may manifest around these days

Yes, the best way to protect to the public from a BSL-4

pathogen (and a possible airborne pathogen) is to

transport it via the main road systems.

The Modified Vaccinia Ankara (MVA) is an attenuated vaccine of a poxvirus . It was licensed and used as a poxvirus vaccine in Bavaria and is a vector for vaccination

against non-poxvirus diseases. (wikipedia)

“We previously evaluated a series of gene-based approaches to developing an Ebola vaccine in Ebola challenge

studies involving nonhuman primates, 10-12 and three early-generation candidate Ebola vaccines were assessed in

clinical trials between 2003 and 2009. 13-15 Because of theoretical safety concerns involving wild-type Ebola

glycoprotein cytopathic effects in cell culture, 7 initial antigen designs included a transmembrane-deleted version of

glycoprotein 13 and a full-length glycoprotein antigen containing a single amino acid mutation. 14 No safety

concerns were identified with these vaccines, but advanced development was not pursued because

immunogenicity and subsequent preclinical efficacy results were deemed to be inadequate.”

13. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine

Immunol 2006;13:1267-77

12. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus

vectors encoding modified GPs. PLoS Med 2006;3(6):e177

14. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic

in healthy adults. Vaccine 2010;29:304-13.

“In addition, cAd3-EBO primes nonhuman primates for a boost with recombinant modified vaccinia Ankara

(MVA) wild-type glycoprotein vaccine, (see previous slide) resulting in more durable protection from challenge at

10 months.” 16

Vaccine: The cAd3 drug substances were manufactured at Advent, a subsidiary of Okairos (now Glaxo

SmithKline), and the drug product (recombinant chimpanzee adenovirus type 3–vectored Ebola vaccine VRC-

EBOADC069-00-VP) was manufactured at the VRC Vaccine Pilot Plant, under contract with the Vaccine Clinical

Materials Program, Leidos Biomedical Research.

“Asymptomatic neutropenia or leukopenia (types of white blood cells) of grade 1 or 2 was observed 3 to 4

days after vaccination in one recipient of the 2×10 10 particle-unit dose and in three recipients of the 2×10 11

particle-unit dose.”

14. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic

in healthy adults. Vaccine 2010;29:304-13.

At this time, the author is currently still searching for an open version of this study. Elsevier, like many other bodies, do not seem to release many free studies into the public

domain. Most are for purchase.

15. Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-

type glycoproteins in a phase I clinical trial. J Infect Dis 2014

One Step Closer to an Ebola Virus Vaccine

Daniel G. Bausch, M.D., M.P.H.&T.M.

For some years, a number of promising vaccine candidates have been identified, with many more in development. The

two leading candidates are vectored vaccines in which the Ebola virus glycoprotein is presented in a replication-

incompetent chimpanzee adenovirus 3 (cAd3) or a replication-competent vesicular stomatitis virus (VSV). Both

vaccines have shown 100% protection in nonhuman primates at 4 to 5 weeks after single doses were administered

and have now been rushed into phase 1 trials in hopes that the promise of a vaccine to help stem the crisis in Africa

can be more than theoretical.

Ledgerwood and colleagues now present in the Journal the first results of the phase 1 VRC 207 trial, a

nonrandomized, open-label trial of two dose levels of a cAd3-vectored bivalent vaccine against the two most virulent

species of ebola virus, Zaire and Sudan.4 They conclude that the vaccine was safe and immunogenic, inducing strong

humoral and cell-mediated responses

4. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in

healthy adults. Vaccine 2010;29:304-13.

The matter is further complicated by a lack of standardization of stock viruses 6 and the fact that, to achieve 100%

mortality in control animals, and thus interpretable results, in studies in nonhuman primates, an extremely

high challenge dose of virus (1000 plaque-forming units) is used, which is probably orders of magnitude higher

than the inoculum that typically infects a human. Until the correlates of immunity are better understood, it is

impossible to say whether the immune response shown at the lower dose in the study by Ledgerwood et al., which

caused fewer side effects, is “good enough.”

Although the results of the trial are indeed promising, questions remain; both immunogenicity and reactogenicity

were dose-dependent. The higher dose, which was associated with minor adverse effects in 70% of the participants,

including one in whom a high fever temperature, 39.9°C) developed, and with transient leukopenia in 20%.

4. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in

healthy adults. Vaccine 2010;29:304-13.

Ledgerwood and colleagues now present in the Journal the first results of the phase 1 VRC 207 trial, a

nonrandomized, open-label trial of two dose levels of a cAd3-vectored bivalent vaccine against the two most

virulent species of ebola virus, Zaire and Sudan.4 They conclude that the vaccine was safe and immunogenic,

inducing strong humoral and cell-mediated responses

These initial clinical data for the Ebola virus vaccine (cAd3-EBO) support the safety and immunogenicity of a single vaccination. The

rates and severity of local and systemic side effects, including fever at higher dose levels, were similar to those observed in previous

studies of other adenovirus vectors. 14,22 In future studies, a fever developing more than 1 day after vaccination or lasting longer

than 1 day may require evaluation to determine additional causes.

22. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci

Transl Med 2012;4:115ra1. 14. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing

Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29:304-13

It was indeed good news that another

‘british nurse’ survives Ebola. ZMAPP

and monoclonal antibodies (and blood

serum), seems to have helped…

Since the first week of January, cases of Ebola have begun to rise again. As the weather improves and becomes warmer, it can be expected that Ebola may be considering a

vacation or two somewhere nice and warmer.

Scientists from the World Health Organisation will meet this month to predict which

strains of flu are likely to be present next winter – and vaccine production will get under

way. But the vaccines will almost certainly be developed to protect against this mutant

strain of H3N2 in case it is still in circulation. Experts hope this winter has just been a

one-off and next year’s jabs will resume the usual effectiveness level of at least 60 per

cent. And they say it is crucial that vulnerable groups receive the vaccine as normal next

autumn as it remains the best way of preventing flu.

So.. Where are these other so-called entities such as the IMF getting this credit from and what is it backed by when it comes to investment returns and profit? George Osbourneseems to believe you can stay a debt while other nations get into debt for a vaccination

programme that is at best, ineffective and at worst, damaging to health.

And, as usual, all of these problems with pathogens is not due to human intervention and

playing mad science. Of course it’s not. It’s “climate change”

(like the climate hasn’t eternally changed again and again and again in times past)

It is also important to note that 2015 is seems to be a big year for pushing all vaccines upon

the populace, including universal vaccines for all manner of virus and bacteria such as

influenza, HIV-1, recombinant GMO derived particulate material, bovine fetal serum,

human genetic matter and post-production residuals. HPV is one to study (MRC-5 cells)

This article is for another presentation but nonetheless, it’s

interesting to note that more virus may very well ‘pop-up’

as 2015 progresses. This year is quite possibly a seminal

year for geo-political changes all around the planet.

Again, this slide belongs in another presentation (soon , but the main point for the viewer to recall is the idea that 2015

will see the birth of many new variants, any of which could turn epidemic upon populations as the year passes

through the seasons.

There has been a rise in plague language,

especially in ‘UK’ with rat sizes and the

increasing population numbers of Rattus

Rattus, and the clinical findings of poison-

resistance in rats

Sometimes, one has to wonder if journalists

even do any basic research. They surely must

know that this lab is only suitable for BSL-3

pathogens and not Ebola, which is a Category

A bioweapon according to CDC and must be

held in a BSL-4 facility. Do YOU, the viewer,

see a potential future problem?

Do check back for updates. This will be added to from time to time as the information appears.

The author will be adding some further studies which have yet to be evaluated, and those findings will be shared when the articles have been

digested properly and cross-referenced.

As this research aligns with other topics included on this site, it would be prudent to check out all the other presentations. Having studied Sugar and metabolism, Vitamin C and starvation (and obesity) vaccines, and autism

disease, they are all connected to this field of study. A healthy you is your best protection from pathogens, viruses and the like. A vaccine is not.

Thank you for taking the time to view this information. If you deem it useful or educational, do please share it where you can. Most of the information

shown is within the public realm. i hold no rights to any of the material contained herein. They are all a collection of ones and zeros on a computer

screen.